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Abstract
Alternative splicing of mRNAs is known to involve a major regulation of gene expression at RNA level in mammalian cells.
The PTEN (Phosphatase and TENsin homologue deleted from the human chromosome 10), TPTE (Transmembrane
Phosphatase with TEnsin homology) and TPIP (TPTE and PTEN homologous Inositol lipid Phosphatase) belong to a family of
dual-specific lipid and protein phosphatases. PTEN is a well characterized tumor suppressor, which plays crucial role in cell
survival, cell cycle regulation, cell proliferation as well as adhesion, motility and migration of cells. The C2-domain of PTEN is
essential for PTEN-functions. We have isolated a novel 1019 bp human TPIP cDNA (TPIP-C2) from a human testis cDNA
library. In silico analysis of the cDNA revealed that it is produced from the TPIP-locus on the human chromosome 13 by
alternative RNA-splicing. It has a unique 59-Alu sequence, a LINE sequence followed by a 582 bp Open Reading Frame (ORF)
encoding a 193 aa polypeptide with a partial phosphatase domain and a C2-domain. TPIP-C2 mRNA is expressed in human
testis and in mouse tissues. Mouse testis and brain showed higher levels of TPIP-C2 mRNA in comparison to the heart, liver
and kidney under normal physiological conditions. TPIP-C2 mRNAs from human and mouse testes show extensive sequence
identity. Over-expression of TPIP-C2 cDNA in HeLa cells strongly (up to 85%) inhibited cell growth/proliferation and caused
apoptosis in a caspase 3-dependent manner. These findings suggest for the first time that a TPIP splice-variant mRNA with a
partial phosphatase domain and a C2-domain is expressed in cells and tissues of human and murine origins under normal
physiological conditions. Inhibition of cell growth/proliferation and induction of apoptosis by overexpression of TPIP-C2
mRNA in HeLa cells suggest that it may be involved in negative regulation of cell growth/proliferation.
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Introduction
Mammalian genomes contain relatively less numbers of genes,
which encode large numbers of proteins. This is effective by
alternative splicing of the primary transcripts to generate splice-
variants (SVs) of mRNAs, which code for isoforms of proteins with
variable functions. The PTEN/MMAC1 (Mutated in Multiple
Advanced Cancers-1)/TEP1 (TEnsin-like Phosphatase-1) was
identified as a tumour suppressor gene from the human chro-
mosome 10q23.3 [1–3]. It is the second most mutated tumour
suppressor after TP53 and is mutated or deleted in a wide variety
of cancers. In addition to genetic mutations, somatic, germ-line
and promoter mutations of PTEN are responsible for Cowden
syndrome (CS), Bannayan-Riley-Ruvalcaba Syndrome (BRRS),
Proteus and proteus-like syndrome etc [4–6]. PTEN acts as a dual-
specific phosphatase, it dephosphorylates both proteins at tyrosine,
serine, and threonine residues and lipid second messengers like
phosphatidyl inositol 3, 4, 5-triphosphate [PI(3,4,5)P3], -3, 5-
diphosphate [PI(3,5)P2], -3, 4-diphosphate [PI (3,4)P2] and -3-
phosphate [PI(3)P] at D3-position, thus antagonizing the PI-3
kinase-AKT mediated cell growth/proliferation signaling pathway
[7–10]. Crystal structure, deletion and mutation studies of PTEN
revealed that the C-terminal C2-domain associates strongly with
the N-terminal phosphatase domain to make the catalytic site
and even small deletion of the C2-domain removes detectable
phosphatase activity [11–14]. Evidence from recent literature
suggests that the C-terminus of PTEN possesses autoinhibitory
function, interfering both the phosphatase and C2-domain and
this is accomplished by direct interaction of the tail region with the
C2-domain [15–17]. It is also reported that PTEN regulates cell
migration through its C2-domain, independent of its lipid-
phosphatase activity and this activity of C2-domain is controlled
by Thr
383 phosphorylation/dephosphorylation [18]. Similarly,
PTEN physically interacts with many proteins, e.g., Thioredoxin-1
(Thx-1), serine/threonine kinase (STK11, also named as LKB1)
and p53 by its C2-domain [19–21]. Interaction of PTEN with p53
facilitates transactivation of p53 and autoregulation of its own
expression and this function is independent of the PTEN-
phosphatase function [22]. Thus, C2-domain of PTEN is crucial
for its biological function.
Other phosphatases of PTEN-family include TPTE and TPIP.
TPTE is a testis-specific gene expressed from the human chro-
mosome 21, while TPIP is expressed from the human chromo-
some 13. Both TPTE and TPIP have multiple splice-variants i.e.,
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28433TPTEa, b, c, d [23–26] and TPIP a, b, c and d [25,26] reported
so far. TPTE is a testis-specific phosphatase, while TPIPa is highly
expressed in testis and brain and at low levels in stomach and
TPIPb is expressed in the testis. The human TPIPc, TPTEa,
TPTEb and TPTEc have four putative transmembrane domains;
TPIPa and TPTEd have three and two putative transmembrane
domains, respectively, whereas TPIPb has no transmembrane
domain. TPIPa and c are localized in the endoplasmic reticulum
(ER) and Golgi, respectively, TPIPb is cytosolic. All TPTE
derivatives are restricted to the ER and Golgi, except TPTEd,
which shows a more diffused pattern of expression. TPTE and
TPIP proteins are expressed in secondary spermatocytes and/or
pre-spermatids. TPIP and TPTE have similar domain-organiza-
tion. TPIPa is reported to be a lipid-phosphatase like PTEN and
has phosphatase activity against the lipid substrates: PI(3,4,5)P3,
PI(3,5)P2, PI(3,4)P2 and PI(3)P, which are second messengers in
cellular signaling pathways [23–26].
In the present study, we have isolated a novel TPIP splice-
variant (TPIP-C2) mRNA from a human testis cDNA library.
TPIP-C2 mRNA can code for a 193 aa putative C2-domain-
like protein. It is produced from the human TPIP-locus on
chromosome 13 by alternative RNA-splicing and expressed in
human testis and mouse tissues. The TPIP-locus of mouse genome
is expressed as TPIP-C2 mRNA in the tissues. Functional assay
showed that ectopic expression of TPIP-C2 cDNA caused up to
85% suppression of cell growth/proliferation and induced apo-
ptosis in human cervical carcinoma (HeLa) cells. Therefore, the
alternatively spliced TPIP-C2 mRNA encoding an isolated C2-
domain-like protein may exist in mammalian cells and tissues and
negatively regulate signaling events involved in regulation of cell
growth/proliferation.
Results
Isolation and characterization of TPIP-C2 cDNA from
human testis
The TPIP-C2 cDNA was isolated as a 1.019 kb cDNA from a
lgt11 human testis cDNA library [27] by screening with a 227 bp
rat genomic simple repeat DNA probe (GenBank Accession No. X
97459) as described in the materials and methods section during
an investigation to look for repeat sequence containing RNAs from
the human genome. Analysis of the 1.019 kb TPIP-C2 cDNA
sequence (GenBank Accession No. FJ969729) was carried out
using standard bioinformatics tools and the summary of the results
is schematically shown in Figure 1A, B, C and Figure S1A, B, C. It
contains a 59-97 nt. (145–241) Alu-repetitive SINE element
belonging to AluSx-class, a 61 nt. (268–328) LINE sequence
belonging to L3CR1 class followed by a 582 nt (340–921)
encoding a 193 aa ORF (Figure 1A). The genomic organization
of TPIP-C2 cDNA was deduced by comparison with the TPIP
locus of human genome sequence, as shown in Figure 1B. TPIP-
C2 is a novel isoform belonging to PTEN-C2 superfamily, though
similar in many ways with the TPIPa, c and d isoforms. It has
some distinct characteristics, such as presence of a repeat-rich 59-
UTR (46% of the 59-UTR is composed of SINE and LINE
sequences) and a 14 nucleotide unique sequence at 39-end, which
has been incorporated from outside the TPIP-locus (Table S1,
Figure 1A, B, C). This may involve trans-splicing, a less frequent
RNA-processing mechanism. In silico analysis mapped the 59-end
of TPIP-C2 to the intron 15 of the human TPIP locus on
chromosome 13 (Figure 1B, Figure S1D). The TPIP-C2 SINE is
unique because it is present in the 59-untranslated region (59-
UTR). In contrast, similar SINE elements are present in 39-UTRs
of several human transcripts (Table S2). It is likely that it may be a
target of small non-coding RNA.
We checked the presence of TPIP-C2 sequence in the human
genomic DNA. Southern blot analysis of genomic DNA from
human peripheral blood lymphocytes using BamH I, EcoR I and
Hind III digestions followed by hybridization of
32P-TPIP-C2-
ORF (603 bp) DNA probe identified genomic DNA fragments of
expected sizes based on in silico analysis of the genomic
organization of the locus (Figure 2A, B). As shown in Figure 2
B, the expected sizes of fragments, which can be detected by TPIP-
C2-ORF probe were calculated from the 119.33 kb human
genomic sequences on chromosome 13 (NT_024524.13). A search
of the cDNA database revealed homology of TPIP-C2 with
TPTE2 and TPTE cDNAs (Table S1). TPTE2 and TPIP-C2
cDNAs contain exactly identical coding region, but differ
significantly with respect to their 59-UTR and 39-UTR regions,
thus suggesting possible differential regulation at RNA level with
respect to expression and translation of these transcripts in cells.
Expression of TPIP-C2 mRNA in human tissues
Expression of TPIP-C2 mRNA was studied by using a human
multiple tissue northern (MTN) blot and
32P-TPIP-C2-ORF DNA
probe. A poly(A)
+ transcript of 2.5 kb was specifically detected in
the human testis RNA but not in the spleen, thymus, prostate,
ovary, small intestine, colon and peripheral blood leukocytes RNA
(Figure 2C). A similar experiment was carried out using a human
multiple tissue expression (MTE) array. A prominent signal was
again specifically detected in the human testis (Figure 2D, row F,
column 8), while RNA from other tissues (Figure 2) was either
negative or showed very low levels of expression. This is in
agreement with the northern blot result. A number of human
cancer cell lines and tissues were negative for TPIP-C2 mRNA
expression (Figure 2D, Figure S2A). The full-length
32P-TPIP-C2
cDNA probe detected strong signals in almost all tissues because of
the SINE and LINE sequences present in the full-length TPIP-C2
cDNA and expression of RNAs containing the SINE and possibly
LINE RNAs in the human cells and tissues, this served as an
internal control (Figure S2B). These results indicate that TPIP-C2
mRNA is predominantly expressed in human testis.
Expression of TPIP-C2 mRNA in mouse tissues
We checked TPIP-C2 mRNA expression in mouse tissues. RT-
PCR analysis was carried out to check whether TPIP-C2-like
mRNA is expressed in mouse tissues or not, although no TPIP
RNA/cDNA has been reported from mouse till date. We developed
a specific RT-PCR assay to distinguish TPIP-C2 transcript from
RNAs produced from other TPIP-isoforms. Based on the sequence
homology, the ORF-primers (P1 and P2) (Figure S1B) are expected
to amplify a 603 bp TPIP-ORF from TPIPa, c, d and -C2
transcripts. Therefore, TPIP-C2-specific primers (P3 and P4) were
designed to specifically amplify a 733 bp product from cellular
TPIP-C2 transcript but not from other related transcripts. Figure
S3A (left panel) shows that TPIP-ORF is negative for P3+P4
primers (lane 4) but positive for P1+P2 primers (lane 3). Hence, the
733 bp amplicon (lane 6) is specific for TPIP-C2 cDNA/mRNA.
Analysis of RNA from the brain, heart, testis, liver and kidney of
adult male mice by RT-PCR showed differential expression of
TPIP-C2 mRNAinthe mouse tissues(Figure S3A,right panel). The
testis and brain showed higher expression of TPIP-C2 mRNA than
heart, liver and kidney. The RT-PCR was again carried out for 20,
25, 30, 35 cycles and normalized to GAPDH and b-actin signals.
This semi-quantitative RT-PCR analysis showed higher levels of
TPIP-C2 mRNA expression in brain and testis in comparison to
heart, liver and kidney of mice under normal physiological
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testis, liver and kidney were purified, cloned and sequenced to
confirm their identity. The TPIP-C2 cDNA sequence (GenBank
Accession No. FJ969730) from mouse testis is identical to that
obtained from human testis, while other tissues showed single
nucleotide changes (Figure S3B, C). These single nucleotide/amino
acid changes such as A350G=Thr 99 Ala, G288A=Arg 78 His in
heart and T612C=Val 186 Ala in kidney may potentially change
Figure 1. TPIP-C2 cDNA, genomic organization of TPIP-locus and PTEN, TPIP, TPTE protein isoforms. (A) TPIP-C2 cDNA (1019 nt)
contains a SINE belonging to the AluSx class and a LINE belonging to the L3CR1 class in its 59-untranslated region (59-UTR) followed by a 193 aa. ORF.
The P1 and P2 primers amplify a 603 bp TPIP-C2 ORF, the P3 and P4 primers are TPIP-C2-specific and amplify a 733 bp product. (B) Comparison of
TPIP-C2 exons with TPIP-isoforms. The 1–23 exons of TPIP gene on the human chromosome 13 and the corresponding exons of TPIP-isoforms are
shown. TPIP-C2 cDNA is shown below and the 59-UTR in shaded box indicates its origin from intron 15. The line below the exons represents CDS and
the corresponding ORF, the extended exon 16, the 15 nt unique sequence to exon-23 of TPIP-C2 are shown. (C) Schematic representation of TPIP-C2
and the related protein isoforms. The 193 aa. TPIP-C2 ORF has a partial phosphatase domain (1–56) and a C2-domain (57–193) identical to TPIPa, c, d
and homologous to PTEN. The structural and functional regions are indicated.
doi:10.1371/journal.pone.0028433.g001
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some other changes such as T241 T/C, G706A, A665G make no
change in the amino acid sequence. Expression of TPIP-C2 mRNA
was also confirmed by northern blot hybridization in different
mouse tissues by using the TPIP-C2-specific 180 bp (BamH I-Dde
I) DNA probe generated from the mouse testis-derived 733 bp RT-
PCRproduct (Figure 3C). Itdetected a prominent mRNAspeciesof
,3.48 kb and some additional smaller transcripts of ,1.45, 1.2 and
0.9 kb in the brain, heart, testis, liver and kidney (Figure 3C). All
these results taken together suggest that the TPIP-C2 transcript is
expressed at different levels in different tissues of mouse under
normal physiological conditions.
Overexpression of TPIP-C2 in HeLa cells caused inhibition
of cell growth/proliferation and induction of apoptosis
We checked possible cellular function of TPIP-C2 mRNA in
human cells. TPIP-C2 cDNA was expressed from pCDNA-TPIP-
C2 plasmid in HeLa cells by stable transfection followed by G418-
selection resulting into G418-resistant colonies expressing TPIP-
C2 mRNA. Overexpression of TPIP-C2 mRNA caused up to 85%
decrease in the number of G418-resistant colony formation. This
is shown by two independent experiments with two different DNA
concentrations (2.5–10 mg DNA per 10 cm plate and 1–5 mg DNA
per well of 6 well plate). The suppression of cell growth/
proliferation increased from 12% to 85% with increasing amount
of cDNA transfected into the cells showing a DNA-dose-
dependent effect (Figure 4A, B). The magnitude of cell growth/
proliferation suppression (Figure 4A, B) can be correlated with the
level of TPIP-C2 mRNA expression measured by RT-PCR in a
DNA dose-dependent manner (Figure 4C). Endogenous expres-
sion of TPIP-C2 mRNA in HeLa cells is also detected by RT-PCR
(Figure 4C lower panel, lane C). The colony morphology and size
also significantly changed due to TPIP-C2 mRNA expression and
there is a direct correlation between the level of TPIP-C2 mRNA
expression and changes in the morphological features of the cells
(Figure 4D). TPIP-C2 cDNA transfected colonies are significantly
Figure 2. Genomic organization and expression of TPIP-C2 mRNA. (A) Southern blot analysis of genomic DNA from human peripheral blood
lymphocytes (PBL) is shown after BamH I (B), EcoR I (E), Hind III (H) digestions and hybridization with [
32P] labeled 603 bp TPIP-C2 ORF-DNA probe.
The cDNA plus ORF is used as a positive control. (B) Restriction map of the human TPIP-C2 gene derived from TPIP-C2 genomic locus spanning
,15.3 Kb. Restriction enzymes (RE) used for the study are: E-EcoR I, H-Hind III, B-BamH I. The expected sizes of respective restriction fragments to be
detected by the TPIP-C2-ORF probe are calculated from the genomic sequence and are given in the table from left to right as per the map. (C) Testis-
specific expression of TPIP-C2 mRNA: Multiple tissue northern (MTN) blot of poly(A
+) mRNAs from the human tissues was hybridized with [
32P]
labeled 0.603 kb TPIP-C2 ORF-DNA probe. A distinct transcript of ,2.5 kb is observed in the human testis. (D) MTE array of poly(A
+) mRNAs from the
human tissues and human cancer cell lines were hybridized with [
32P] labeled 0.603 kb TPIP-C2 ORF-DNA probe. The testis showed strongest signal
while other tissues showed very weak signal. PBL: Peripheral blood leucocytes.
doi:10.1371/journal.pone.0028433.g002
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PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28433Figure 3. Expression of TPIP-C2 mRNA in mouse tissues. (A) RT-PCR of TPIP-C2 from the mouse tissue RNA. RT-PCR of cellular GAPDH and b-
actin mRNAs are shown as internal reference. (B) Normalized RT-PCR signals: the TPIP-C2 mRNA signal was normalized to GAPDH (TPIP-C2/GAPDH)
and b-actin (TPIP-C2/b-actin) mRNA signals and plotted. The data represents average of two independent experiments. (C) Schematic representation
of the mouse TPIP-C2 probe. The 733 bp mouse TPIP-C2 RT-PCR product was purified, cloned and digested by restriction enzymes (as shown) and the
180 bp BamH I/Dde I DNA fragment was used as the probe. Northern blot hybridization shows TPIP-C2 mRNA expression in the mouse tissues by
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these morphological changes in the colonies as a function of
increasing amount of TPIP-C2 mRNA expression is shown in
Figure 4D (lower panel). The number of defined colonies
decreased, the number of single cells increased and the number
of loose colonies remained similar suggesting the cell growth/
proliferation suppression effects of TPIP-C2 mRNA. The cells
appeared to be growth-arrested. The level of endogenous TPIP-
C2 mRNA did not alter even after 10 mg vector DNA transfection
indicating there was no effect on the cells due to the method of
transfection or the vector DNA.
From these results it is clear that TPIP-C2 mRNA is a splice
variant (SV) from the human TPIP-locus and the TPIP-C2 protein
product is completely identical with the C2-domain of other TPIP
isoforms (TPIPa, c, d). Therefore, we inserted a HA-tag to make
pCDNA-TPIP-C2-HA expression plasmid so that upon transfec-
tion, the protein can be detected by western blot using anti-HA
antibody. Expression of HA-tagged TPIP-C2 protein is shown in
HeLa cells transfected with the HA-tagged plasmid (Figure 4E).
Antibody against the HA-tag identified a band of approximately
30 kDa size demonstrating that the TPIP-C2 mRNA was expressed
into the TPIP-C2 protein after transfection of the cells. To correlate
thecell growth/proliferation suppression effectwith over-expression
of TPIP-C2 protein, we looked for specific expression of active
caspase 3 (17 kDa protein). Caspase 3 is found as an inactive
32 kDa proenzyme and during apoptosis, initiator caspase cleaves
the procaspase 3 into 17–19 kDa and ,12 kDa active forms of
caspase 3. Immunoblot analysis of the vector and TPIP-C2-HA
transfected cell extracts showed expression of activated caspase 3 in
the TPIP-C2-HA transfected cells, which is a hallmark of apoptosis
(Figure 4E). The caspase 3 antibody used here is specific for the
cleaved 17 kDa protein. Expression of endogenous b-actin protein
is shown as internal control. Therefore, the cell growth/prolifera-
tion suppression effects can be correlated with expression of the
TPIP-C2 protein from the transfected cDNA and TPIP-C2 can
cause apoptosis in HeLa cells.
To further validate the growth/proliferation suppressive effect
of TPIP-C2 in HeLa cells, cell proliferation was measured by a
cell viability assay (MTT) in TPIP-C2 transfected HeLa cells. The
transfection efficiency was ,40% to 50% as determined by
transfection of 1 mg of pEGFP-N2 plasmid in HeLa cells
(Figure 5A). As shown in Figure 5B, the cell viability/proliferation
inhibition increased from 45% to 62% with the increase in amount
of TPIP-C2-HA DNA transfected (0.25 to 1.0 mg) into the cells. As
described above, over-expression of TPIP-C2-HA protein caused
activation of caspase 3 protein, which is actively involved in
apoptosis. The cell cycle status was also analyzed by flow
cytometry by measuring the fluorescence from the cells stained
with propidium iodide. With the increase in TPIP-C2-HA DNA
transfection, the percentage of cells in the G1-phase decreased and
the percentage of apoptotic cells in the sub-G1 region increased
from 8.7% to 29.5% (Figure 5C). The morphology of the cells
transfected with increasing amount of TPIP-C2-HA DNA was
observed by bright field microscopy. These cells showed altered
morphology in comparison to the vector DNA-transfected cells.
The number of floating cells also increased with the increase in
amount of transfected DNA (Figure 5, lower panel). These results
clearly demonstrate that TPIP-C2 is a potent activator of cell cycle
arrest and apoptosis in HeLa cells.
Discussion
TPIP-C2 mRNA and its expression in human and mouse
tissues
In this study, we report a new isoform of TPIP mRNA, which
was isolated from the human testis cDNA library and we named it
as TPIP-C2 mRNA, this is in addition to the previously described
TPIPa, b, c and d isoforms. Mammalian genome maintains the
genomic DNA as the blue print of the organism with high degree
of consistency and transcribes it into large numbers of RNAs with
high degree of fidelity and variability. Primary transcripts from
many human genes are processed by different posttranscriptional
mechanisms to produce isoforms of RNAs and proteins for
carrying out various cellular functions [28]. One of such examples
is the human TPIP locus, which is capable of generating multiple
mRNA isoforms by alternative splicing. Since there is only a single
copy of TPIP gene in the human genome, TPIP-C2 mRNA must
be generated by alternative splicing of the TPIP pre-mRNA
utilizing cryptic or alternative splice sites. TPIP-C2 cDNA has
retrotransposon-derived repeat sequences in the 59-end (1–324 nt)
region, which has no homology with the TPIP and TPTE isoforms
but it shows very high sequence similarity with the 2727 nt of
TPIP-pseudogene present on chromosome 13. There is also a
processed TPIP pseudogene on chromosome 13 (ref|NR_
002815.1|). The exon 16 of TPIP-C2 transcript is extended into
intron 15 and it also includes a part of the intron 15 in the mature
transcript. Thus, it represents an ‘‘exon-extended’’ model of
alternative splicing. The extended 59-exon 16 into the intron 15
forms the 59-UTR and genomic Southern hybridization with
TPIP-ORF probe detected corresponding chromosomal fragments
suggesting that TPIP-C2 transcript has been generated by
alternative splicing (Figure 1, 2). Alterations in splicing and
differential expression of splice-variants (SVs) have been reported
for many other genes involved in various cancers and also in other
diseases. Novel SVs of PTEN retaining part of introns also have
been reported. The PTEN-SVs showed differential expression in
heritable and sporadic breast cancers, CS patients and normal
healthy controls. Some PTEN-SVs showed higher expression in
human fetal tissues in comparison to adult tissues. This is one
example showing functional regulation and inactivation of the full-
length gene in the inherited cancer syndromes by its splice variants
[29].
The TPIP-C2 SINE is also present in 39-UTR of many other
human transcripts indicating its functional significance. Since Alu
sequences are abundant and polymorphic in the human genome
and most of the human genome is transcriptionally active, we
expect presence of Alu sequences in several RNAs. This may have
functional consequences and evolutionary significance. SINE and
LINE elements located in promoters of some human genes have
been reported to contain high-affinity binding sites for hormone
receptors, their presence in enhancers suggest role of these mobile
DNA elements in regulation of gene expression [30,31]. The
functional significance of LINE and SINE sequences in the 59-
UTR of TPIP-C2 mRNA needs to be further investigated.
TPIP-C2 mRNA is strongly expressed in human testis as a
2.5 kb mRNA and weakly expressed in other tissues (Figure 2). It is
differentially expressed in major mouse tissues; the testis shows
maximum expression followed by the brain, kidney, heart and
liver (Figure 3). TPIP-C2 mRNA expression in mouse tissues
using random-primed [
32P] labeled 180 bp TPIP-C2-specific DNA probe.
32P-labeled random-primed GAPDH (452 bp) probe was used as an internal
control. Methylene blue staining of the ribosomal RNAs on the RNA-filter was used as a loading control. M: Marker, Lc: 20 ng of 0.74 kb DNA as
loading control, B: brain, H: heart, T: testis, L: liver and K: kidney.
doi:10.1371/journal.pone.0028433.g003
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expressed RNA is restricted to testis. The mouse TPIP-C2 mRNA
is detected as a 3.5 kb RNA and is distinctly different from
PTEN2, a testis-specific RNA of 2.7 kb [32] and other TPTE-
isoforms of mouse. As there is no TPIP mRNA reported from
mouse yet, this is the first study to identify a TPIP mRNA
expressed in a wide variety of mouse tissues under normal
physiological conditions. The nucleotide sequence of TPIP-C2
cDNAs generated by RT-PCR from mouse and human testis are
highly homologous indicating their evolutionary conservation.
However, the relationship of the 1 kb human TPIP-C2 cDNA, the
2.5 kb human mRNA and the 3.5 kb mouse mRNA need further
investigation. It will be interesting to study the localization and
function of TPIP-C2 isoforms in human cells and mouse tissues.
Figure 4. Cell growth/proliferation-suppression by TPIP-C2 cDNA in HeLa cells. (A) HeLa cells were transfected with pCDNA-TPIP-C2
plasmid DNA (2.5, 5.0 and 10 mg DNA in a total of 10 mg of DNA per 6-well plate or with pCDNA-TPIP-C2 plasmid (1, 2, 3 and 5 mg DNA) in a total of
5 mg DNA per well in 6-well plate in duplicates, stable G418-resistant colonies were selected by 0.6 mg/ml G418 for three weeks, and their number
was counted. (B) The TPIP-C2-transfected G418-resistant colonies of HeLa cells with respect to transfection of 10 mg of vector DNA (V); 2.5, 5.0, 7.5,
10 mg of TPIP-C2 DNA and negative control (no DNA). (C) Expression of TPIP-C2 mRNA by RT-PCR in the untransfected and transfected HeLa cells.
Cells were transfected with the indicated amount of plasmid DNA (total amount of DNA was made 10.0 mg with vector). RT-PCR of cellular GAPDH
and b-actin mRNA are shown as internal reference. (D) Morphology of the G418-resistant TPIP-C2 cDNA transfected and vector transfected HeLa cell
colonies (upper panel). Quantification of TPIP-C2 transfected G418-resistant HeLa cells showed decrease in the number of defined colonies and
increase in the number of single cells with increasing DNA (1, 2, 3 and 5 mg/well) (lower panel). *: Data represent average values of duplicates from
two independent experiments. (E) Expression of HA-tagged TPIP-C2 protein in TPIP-C2-HA transfected HeLa cells by Western blot. HeLa cells were
transfected with pCDNA-TPIP-C2-HA plasmid (1 and 2 mg) or pCDNA vector (2 mg). Expression of active caspase 3 (cleaved caspase 3) was detected in
cell extracts by Western blot analysis. Expression of cellular b-actin protein is shown as an internal reference.
doi:10.1371/journal.pone.0028433.g004
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in the mouse and human tissues may indicate that they may have
different functions in the two species. However, it may be possible
that TPIP-C2 mRNA has a generalized function required for
normal cellular physiology thus expressed in many cell types/
tissues of mouse in contrast to PTEN2, which is a Golgi-associated
lipid phosphatase and may have a specialized function during
development and differentiation of sperms in testis [32].
TPIP-C2 protein and its effect
The TPIP-C2 protein belongs to the PTEN-C2 superfamily of
phosphatases. The three-dimensional structure of PTEN provides
a deep insight into potential mechanisms by which the PTEN
phosphatase can recognize and dephosphorylate its 3-phosphate-
containing phospholipid substrates. The PTEN-C2 domain lacks
the canonical Ca
2+ ligands, and thus it is similar to the C2 domains
of the Ca
2+-independent protein kinase C (PKC)-isotypes [11].
Classically, C2 domains have a stable b-sheet scaffold, which
allows them to fold autonomously. This scaffold allows the
emergence of variable loops at the top and bottom of the domain.
The b-scaffold probably allows them to bind phospholipids in a
Ca
2+-dependent manner as shown for C2A-domain of synapto-
tagmin I [33]. PTEN is known to bind phospholipid membranes in
vitro via its C2-domain and mutation of basic residues in this region
reduces PTEN’s membrane affinity and its ability to suppress
growth of glioblastoma tumor cells [11]. The CBR3 loop in
PTEN-C2 domain plays central role in membrane interaction,
binding and function of PTEN [34]. TPIP-C2 has a partial
phosphatase domain and a C2-domain. It has two conserved
hydrophobic residues, Lys-140 and Tyrosine-141 at the CBR3 tip
Figure 5. Cell growth/proliferation-suppression and apoptosis by expression of TPIP-C2 in HeLa cells. (A) HeLa cells were transfected
with 1 mg CMV-enhanced GFP (pEGFP-N2) plasmid and the transfection efficiency (,40%–50%) was calculated by counting ,1000 cells/well. (B) HeLa
cells were transfected with pCDNA-TPIP-C2-HA plasmid DNA (0.25, 0.5 and 1.0 mg DNA in a total of 1.0 mg of DNA per 24-well plate in triplicates).
Viable cells were quantitated by using MTT assay. Data plotted shows means 6 SEM of triplicate wells. (C) Flow cytometric analysis of HeLa cells
transfected with TPIP-C2-HA plasmid. DNA was stained with propidium iodide and DNA content was determined by flow cytometry 36 h post-
transfection. Data are presented as percentage apoptotic (M1), G1 phase (M2), S phase (M3) and G2/M phase (M4). Morphology of HeLa cells after
transfection with TPIP-C2-HA plasmid (1.0, 2.0 and 4.0 mg), showing attached and floating cells visualized under a bright field microscope. This is
representative of three independent experiments. AP: Apoptotic, Vector: transfected with 2 mg pCDNA 3.1 plasmid. All experiments were performed
36 h post-transfection.
doi:10.1371/journal.pone.0028433.g005
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lipid bilayer, therefore, probably it can act in a similar fashion like
the PTEN-C2 domain. PTEN causes negative regulation of cell
growth/proliferation by downregulating the effects of PI-3kinase.
Recent studies have highlighted PTEN as an inducer of apoptosis
in cancer cells [35] and the p73/PTEN protein complex can act as
a co-activator of apoptosis [36].
Interestingly, over-expression of TPIP-C2 mRNA in HeLa cells
also showed similar effects like cell cycle-arrest, suppression of cell
growth/proliferation and induction of apoptosis like PTEN
(Figure 4 and 5). The effect of TPIP-C2 was observed in a
caspase-3 dependent manner as shown by the expression of
activated caspase 3 protein (Figure 4). The TPIP-C2 cDNA
transfected G418-resistant cells showed more loose colonies and
hardly any well defined colony. The morphology of the transfected
cells at higher magnification looked more like growth-arrested cells
and after transfection, there was hardly any cell proliferation
indicating TPIP-C2 mRNA is a potent inhibitor of cell growth and
proliferation. Over-expression of TPIP-C2 by transient transfec-
tion caused increase in the number of floating cells with severe
altered morphology and increased sub-G1 apoptotic population of
cells in a dose-dependent manner indicating that TPIP-C2 is a
potential inducer of apoptosis (Figure 4 and 5). It was also
observed that HeLa cells have endogenous TPIP-C2 mRNA as
detected by RT-PCR. This result is in correlation with the MTE
blot, where testis showed highest level of expression but other cell
types expressed very low levels of TPIP-C2 mRNA (Figure 2).
It has been reported that isolated PTEN C2-domain can inhibit
cell migration in U373 cells [18] and during epithelial-to-
mesenchymal transition (EMT) of developing chick embryonic
mesoderm [37]. It has been also reported that the double
phosphatase-deficient PTEN (C124S) [38] and the lipid-phospha-
tase-dead PTEN (G129E) [39] also inhibited cell invasion in case
of glioma cells and bladder cancer cells similar to the wild type
PTEN. Recently, it has been reported that PTEN-C2 domain can
decrease angiogenesis and VGEF-expression suggesting phospha-
tase-dependent and -independent functions of PTEN in HepG2
cells [40]. Interestingly, more than 40% of mutations in PTEN
have been mapped to the C2-domain [14]. Recently, the PTEN-
C2 domain has been reported to cause inhibition of transcription
of U6 snRNA [41]. Similarly, the C2 domain of perforin has been
shown to mediate Ca
2+-dependent membrane binding [42].
Natural killer cells and cytotoxic T lymphocytes produce perforin
and granzyme. Perforin binds to cell membrane, oligomerizes,
makes pores in the membrane and delivers the proapoptotic
granzyme to kill virus-infected and neoplastic cells. This example
links C2 domain to cell growth inhibition, cytotoxicity and
apoptosis. All these observations suggest that C2-domain may be
crucial for regulation of cell migration, cell invasion and cell death.
The present study shows function of TPIP-C2-domain in negative
regulation of cell growth/proliferation and as a potential inducer
of apoptosis. TPIP-C2 mRNA/protein may negatively regulate
cell growth/proliferation by cell cycle arrest and apoptosis in
mammalian cells. Endogenous expression of the TPIP-C2 protein
needs to be studied in mammalian cells and tissues for its function.
Taken together, TPIP-C2 may be a Ca
2+-independent PTEN-like
C2-domain protein, probably membrane localized, and it induces
apoptosis and negatively regulates cell growth/proliferation
possibly as a dominant negative molecule by interfering with
proteins involved in the interactions of extracellular matrix
(ECM) and cell surface associated as well as intracellular proteins.
The detailed molecular mechanism of the cell growth/prolifer-
ation inhibition by TPIP-C2 mRNA/protein needs further
investigation.
Materials and Methods
Sequence analysis, Database searches
The 1.019 kb TPIP-C2 cDNA was sequenced and analyzed
online using BLAST, ORF finder and RepeatMasker for genomic
localization, possible ORF and repeats. CLUSTAL-W amino acid
sequence alignment and Kyte and Dolittle hydropathy score were
carried out, genomic organization of TPIP-C2 was found by
comparing with the 119.33 kb human genomic sequence on
chromosome 13 (NT_024524.13) by BioEdit online. The 59 splice
site was identified by comparing TPIP-C2 cDNA with the
genomic contig (NT_024524.13). Prediction and comparison of
domains was carried out by ELM, SMART through ExPASy
Proteomics tools.
Reagents, cDNA library and antibodies
Molecular biology and tissue culture grade materials and
reagents were purchased from Sigma-Aldrich (U S A), New
England Biolabs and Promega (U S A), synthetic oligonucleotides
were from Life Tech. (U S A) and Microsynth (Switzerland),
Lipofectamine
TM 2000 (Invitrogen), the human testis lgt11 cDNA
library, the human RNA-blots for expression analysis and pEGFP-
N2 plasmid were from Clontech (U S A). The radioisotope,
[a-
32P]dATP (specific activity=4000 Ci/mmole) was from BRIT,
India. Anti-b-actin monoclonal antibody (A5316), anti-HA-
antibody (H9658), anti-caspase 3 active (C8487), MTT (M2128),
Propidium iodide (P4170) were from Sigma-Aldrich.
DNA constructs, oligonucleotides, genomic DNA, cells
and mice
The 1.019 kb TPIP-C2 cDNA was isolated from a lgt11
human testis cDNA library [27] by a 227 bp rat genomic simple
repeat DNA probe isolated in this laboratory [43]. The l-clone
was digested by EcoR I and subcloned into EcoR I site of
pBluescript vector (pBS-TPIP-C2 plasmid). The TPIP-C2 cDNA
was also subcloned into EcoR I site of pCDNA3.1 vector
(pCDNA-TPIP-C2 plasmid) for expression in mammalian cells.
To check the expression of TPIP-C2 protein, nine aa HA-tag was
introduced in the pCDNA-TPIP-C2 plasmid just before the stop
codon in the TPIP-C2 ORF by circular PCR using Pfu Turbo
DNA polymerase (Stratagene) and Dpn I digestion to make
pCDNA-TPIP-C2-HA tagged plasmid. The PCR reaction
contained 16 PCR buffer, 25 pmole primers (TPIP-C2-HA
primers), 1.0 ng pCDNA-TPIP-C2 template, and 2.5 U Pfu DNA
polymerase. The PCR cycle parameters were: initial denaturation
at 95uC for 4 min followed by 35 cycles of denaturation at 95uC
for 45 sec, annealing at 54uC 45 sec, polymerization at 68uC for
15 min and a final extension of 10 min at 72uC. The 733 bp
TPIP-C2 RT-PCR products (described below) from the mouse
tissues were cloned into pTZR/T TA-vector (pTZ-TPIP-C2
plasmids). The pBS-TPIP-C2 and pTZ-TPIP-C2 plasmids were
used for DNA sequencing. The following forward (f) and reverse (r)
oligonucleotides were used as primers for PCR and RT-PCR.
GAPDH: 59-ACCACAGTCCATGCCATCAC-39 (f) and 59-
TCCACCACCCTGTTGCTGTA-39 (r); b-actin: 59-TTCTA-
CAATGAGCTGCGTGT-39 (f) and 59-AGGATCTTCATGA-
GGTAGTC-39 (r); TPIP-ORF: 59-AAGAATAAGCTTATGG-
TTTGTGCCCTCCTTATTG-39 (P1), 59-TCATTGAAGCTT-
CATTTCTCGCCAAAAAGTATCTCCA-39 (P2); TPIP-C2: 59-
ATACCATGTATGTTCTTGAACT-39 (P3) and 59- GGATTG-
GAGAGCGGGGATT-39 (P4). TPIP-C2-HA: 59-TACCCA-
TACGATGTTCCAGATTACGCTTGACTTCCAATGATGT-
TGTAG-39 (f) and 59-TCAAGCGTAATCTGGAACATCG-
TATGGGTATTTCTCGCCAAAAAGTATCTC-39 (r).
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blood lymphocytes, human cervical carcinoma (HeLa) cells were
from ATCC (U S A) and 12–14 weeks old Swiss albino male mice
were obtained from the Animal house of Jawaharlal Nehru
University. All experimental protocols involving the use of animals
were reviewed by the Institutional Animal Ethics Committee
(IAEC); registration No. 19/1999 (CPCSEA), dated 10.03.1999,
IAEC code No 14/2006, Jawaharlal Nehru University, New
Delhi, India. The molecular biology methods were followed as
described earlier [44].
Northern blot hybridization
Total cellular RNA was isolated from fresh mouse tissues with a
few modifications. Northern blot hybridization was carried out as
described earlier [43]. Briefly, 20 mg of total RNA was denatured
and resolved in 1.5% formaldehyde-agarose gel, transferred to
nylon membrane (Biodyne A, Pall) by vacuum-blotting and the
RNA-filter was pre-hybridized and hybridized in 50% formamide-
based hybridization mixture with random-primed
32P-labeled
mouse TPIP-C2-specific 180 bp cDNA probe (specific activity
.10
8 cpm/mg) for 16–18 h at 42uC. The RNA-filter was
stringently washed and exposed to X-ray film with intensifying
screens at 280uC for 2–3 days and developed for autoradiogra-
phy. The human multiple tissue northern (MTN, Clontech, 7759-
1) and multiple tissue expression (MTE, Clontech, 7775-1) array
RNA blots (Clonetech, U S A) were hybridized with
32P-labeled
TPIP-C2-ORF DNA probe as per the manufacturer’s instructions.
The amount of RNA per lane on Poly A
+ MTN blot used in
Figure 2B is adjusted to obtain consistent signal for a house
keeping gene across all lanes. For this reason, the actual amount of
RNA loaded may vary slightly between samples.
Southern blot hybridization
Genomic DNA was isolated from human peripheral blood from
healthy individual with consent. Twenty microgram genomic
DNA was digested by BamH I, EcoR I and Hind III, elec-
trophoresed by agarose gel and southern hybridized with random
primed
32P-TPIP-C2-ORF DNA probe and detected by autora-
diography [44].
Transfection of HeLa cells
HeLa cells were seeded at 0.15610
6 cells/ml density in 2 ml in
6-well plates, 18 h before transfection and transfected by calcium
phosphate or Lipofectamine
TM 2000 in duplicates with pCDNA-
TPIP-C2 plasmid DNA (i.e., 2.5, 5.0 and 10 mg) in a total amount
of 10 mg DNA per 10 cm plate or 0, 1, 2, 3 and 5 mg DNA in a
total amount of 5 mg DNA per well in six-well plate for 12 h by
calcium phosphate method. The pCDNA3.1 (+) vector DNA was
used to compensate the total amount of DNA up to equal amount
per well. The transfection medium was replaced by fresh medium
and cells were allowed to grow for 24 h followed by addition of
selection medium containing 0.6 mg/ml geneticin (G418, Life
Tech., U S A) for 3 weeks. The medium was changed every third
day until G418-resistant colonies developed, which were then fixed
by methanol, stained with Giemsa stain, observed, counted and
photographed by a phase-contrast microscope. HeLa cells were
transiently transfected in duplicates with different amounts (1 to
10 mg) of pCDNA-TPIP-C2 plasmid DNA in a total amount of
10 mg of DNA compensated with the vector DNA by calcium
phosphate method and 24 h post-transfection, cells were harvest-
ed, total cellular RNA was isolated and used for RT-PCR. HeLa
cells were also transiently transfected with pCDNA-TPIP-C2-HA
plasmid DNA, pEGFP-N2 or pCDNA 3.1 (vector) with 2 mg and
4 mg DNA per well in six-well plate for 6 h in serum free medium
by using Lipofectamine
TM 2000 reagent as per the supplier’s
instructions. After 36 h post-transfection the cells were visualized
and photographed in bright field and fluorescence settings of the
microscope. Cells were harvested and processed for western blot
analysis or cell cycle analysis by FACS.
Western blot analysis
The HeLa cells were harvested 36 h after transfection, washed
with cold PBS and extracted in lysis buffer (20 mM Tris-HCl,
pH 8, 250 mM NaCl, 1 mM DTT, 2 mM EDTA, 0.5% NP-40,
1% Triton X-100, 10 mg/ml leupeptin, 10 mg/ml aprotinin,
0.5 mg/ml benzamidine, 100 mM PMSF and 2 mM sodium
orthovanadate). After 30-min incubation on ice, the lysates were
cleared by centrifugation at 12000 rpm for 30 min at 4u C.
Protein concentration was estimated using Bradford assay.
Approximately, 30–60 mg protein was resolved by 12% SDS-
PAGE, transferred to nitrocellulose membrane (Bio-Rad). Western
blots were carried out by using anti-HA antibody for TPIP-C2-HA
protein, anti-caspase 3 for active caspase 3 and anti-b-actin
antibody. The blots were developed by Super Signal West Pico
Chemiluminescence reagent (Pierce).
RNA isolation and RT-PCR
RNA was isolated from mouse tissues and human cells. First
strand cDNAs were synthesized from 1.0 mg of total RNA with
0.5 mg of oligo dT [59-(dT)15-39] primer, 0.5 mM dNTPs, 20 U
RNasin and 100 U of M-MLV Reverse Transriptase in 16 M-
MLV RT-reaction buffer in 25 ml. First strand cDNA mixture was
used as template and pCDNA-TPIP-C2 plasmid was used as
positive control (Pc) for PCR. The reaction contained 16 PCR
buffer (75 mM Tris.Cl pH 9.0, 50 mM KCl, 20 mM (NH4)2SO4,
0.2 mM dNTPs, 2.0 mM MgCl2, 25 pmole primers (12.5 pmole
each), 1.0–5.0 ml1
st strand cDNA templates and 1.0 U Taq DNA
polymerase. The PCR cycle parameters were initial denaturation
at 94uC for 4 min followed by 20–35 cycles of denaturation at
94uC for 45 sec, annealing at 68uC (TPIP-ORF) or 51uC (TPIP-
C2 and b-actin), 60uC (GAPDH) for 45 sec-1 min, polymerization
at 72uC for 1 min and a final extension of 10 min at 72uC. TPIP-
ORF primers amplified a 603 bp C2-ORF from human TPIPa, c
and d, TPTEa, b, c mRNAs, whereas, TPIP-C2 primers are
specific for the TPIP-C2 transcript and amplified a 733 bp
amplicon. The 311 bp b-actin and 452 bp GAPDH products
were used as control and normalization signals. The PCR products
(1/10
th for GAPDH, b-actin and 1/5
th for TPIP-C2) were
electrophoresed in 1.5% agarose-TBE gels, photographed by an
AlphaImager 3400 gel-documentation system and densitometry of
specific DNA bands was carried out (Integrated Density Value or
IDV) by the AlphaImager software.
Cell proliferation measurement by cell viability assay
(MTT)
Seventy thousand cells were plated per well in 24 well plate and
transfected in triplicates with 0.25 mg, 0.5 mg and 1.0 mg of TPIP-
C2-HA plasmid for 6 h by using Lipofectamine
TM 2000 reagent in
serum free medium as per the supplier’s instructions. After 36 h
post-transfection 100 ml MTT (5 mg/ml) was added to each well
and incubated at 37uC. After 2 h MTT was solubilized by
addition 500 ml of MTT solvent (5 mM HCl, 0.1% Nonidet P-40
in isopropanol) and incubated for another 1 h at 37uC. The
absorbance was measured spectrophotometrically at 590 nm and
plotted. The data were represented as mean 6 SEM from three
independent transfection experiments and each experiment was
repeated twice.
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HeLa cells were transfected with TPIP-C2-HA plasmid in six
well plates as described above and harvested 36 h post-
transfection. Cells were trypsinized, washed twice with ice-cold
PBS, fixed in 70% ethanol in ice-cold PBS for 2 h at 4uC. For flow
cytometric analysis, the cells were incubated with 0.1 mg/ml
RNase A at 37uC for 1 h, stained with 50 mg/ml propidium iodide
for 15–20 min on ice, and then measured by flow cytometry using
FACSCalibur (Becton Dickinson, San Jose, CA, U S A) Cell Quest
software for acquisition and analysis. A minimum of 20,000 events
were recorded for each sample.
Supporting Information
Figure S1 (A) TPIP-C2 cDNA (1.019 kb inserted DNA) is
cloned at EcoR I site of pBSKII
+ (pBluescript) vector. (B) TPIP-C2
cDNA nucleotide sequence and predicted amino acid sequence.
(C) TPIP-C2-SINE and TPIP-C2-LINE sequences are compared
with AluSx and LINE (L3/CR1) repeat sequences, respectively.
The transition and transversion in the sequences are indicated. (D)
Comparison of TPIP-C2 with the TPIP genomic contig on human
chromosome 13. TPIP exons and introns with respect to human
DNA sequences from the clone RP11-408K19 on chromosome 13
[AL590076]. The introns are depicted as dotted line and exons as
black boxes. The number below the exons represents length of
respective exon. The exon sequences corresponding to the
chromosome 13 genomic regions are mentioned (upper panel).
TPIP-C2 exons and introns are with respect to human DNA
sequence from the clone RP11-408K19 on chromosome 13
[AL590076] (lower panel).
(PDF)
Figure S2 (A) Sources of human cells and tissues for the mRNAs
used in the dot blots. (B) Hybridization of the MTE-blot with [
32P]
labeled 1.019 kb full length TPIP-C2 cDNA probe showing
homologous RNA expressions due to presence of SINE/LINE
sequences present in the full length TPIP-C2 cDNA. Almost all
samples show the signals. A number of controls are indicated at
the right hand side of the MTE blot.
(PDF)
Figure S3 Expression of TPIP-C2 mRNA in mouse tissues. (A)
TPIP-ORF amplicon is 605 bp (339–921 nt) and TPIP-C2
amplicon is 733 bp (285–2017 nt) as shown by PCR/RT-PCR
products amplified by using P1+P2 and P3+P4 primers,
respectively. TPIP-ORF primers contain extra flanking sequences
and Hind III site at their 59-ends, thus, instead of 582 bp
amplicon, it amplifies 605 bp DNA. Establishment of TPIP-C2-
specific PCR assay (top panel), Lane 1 and 2: pCDNA-TPIP-C2
plasmid control for TPIP-ORF and TPIP-C2 PCR, lane 3 and 5:
TPIP-ORF PCR with ORF 339–921 and ORF 285–1087
templates, lane 4: ORF 339–921 and b-actin templates were
mixed and PCR-amplified for TPIP-C2 and b-actin (311 bp)
products with respective primers, lane 6: TPIP-C2 PCR from
ORF 285–1087 template, TPIP-C2 plasmid PCR with 10
4–10
1
copies of the plasmid template (bottom panel) showing the
sensitivity of PCR reaction at 10
1 copy number. (B) Chromato-
grams of DNA sequencing of one each type of representative RT-
PCR products cloned from the mouse tissues showing single
nucleotide changes from the expected sequence. (C) The amino
acid changes with respect to the single nucleotide changes in
TPIP-C2 193 aa. ORF are shown. M: Marker, Pc: positive
control, Lc: 20 ng of 0.74 kb DNA as a loading control for
densitometric measurements, B: brain, H: Heart, T: testis, L: liver
and K: kidney of mouse.
(PDF)
Table S1 Homology of TPIP-C2 CDNA with human genome.
(DOC)
Table S2 Presence of TPIP-C2 SINE and LINE in human
transcripts.
(DOC)
Acknowledgments
We thank Dr. Niti Puri, SLS, JNU for the pEGFP-N2 plasmid.
Author Contributions
Conceived and designed the experiments: PCR RRM GDB. Performed
the experiments: RRM JKC GDB. Analyzed the data: RRM JKC GDB
PCR. Contributed reagents/materials/analysis tools: PCR. Wrote the
paper: RRM PCR.
References
1. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997)
Identification of a candidate tumor suppressor gene, MMAC1, at chromosome
10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 352–
362.
2. Li DM, Sun H (1997) TEP1, encoded by a candidate tumor suppressor locus, is
a novel protein tyrosine phosphatase regulated by transforming growth factor 1.
Cancer Res 57: 2124–2129.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain, breast, and prostate
cancer. Science 275: 1943–1947.
4. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, et al. (1997) Germline mutations of
the PTEN gene in Cowden disease, an inherited breast and thyroid cancer
syndrome. Nat Genet 16: 64–67.
5. Gustafson S, Zbuk KM, Scacheri C, Eng C (2007) Cowden syndrome. Semin
Oncol 34: 428–434.
6. Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN
tumor suppressor pathway. J Clin Oncol 22: 2954–2963.
7. Wang X, Jiang X (2008) PTEN: a default gate-keeping tumor suppressor with a
versatile tail. Cell Res 18: 807–816.
8. Carnero A (2010) The PKB/AKT pathway in cancer. Curr Pharm Des 16:
34–44.
9. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, et al. (1997) PTEN, the tumor
suppressor from human chromosome 10q23, is a dual-specificity phosphatase.
Proc Natl Acad Sci U S A 94: 9052–9057.
10. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1,
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-
triphosphate. J Biol Chem 273: 13375–13378.
11. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, et al. (1999)
Crystal structure of the PTEN tumor suppressor: implications for its
phosphoinositide phosphatase activity and membrane association. Cell 99:
323–334.
12. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, et al. (2000)
Stabilization and productive positioning roles of the C2 domain of PTEN tumor
suppressor. Cancer Res 60: 7033–7038.
13. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR (2000) Phosphorylation of
the PTEN tail regulates protein stability and function. Mol Cell Biol 20: 5010–8.
14. Eng C (2003) PTEN: One gene, many syndromes. Hum Mutat 22: 183–198.
15. Das S, Dixon JE, Cho W (2003) Membrane-binding and activation mechanism
of PTEN. Proc Natl Acad Sci U S A 100: 7491–7496.
16. Leslie NR, Yang X, Downes CP, Weijer CJ (2005) The regulation of cell
migration by PTEN. Biochem Soc Trans 33: 1507–1508.
17. Odriozola L, Singh G, Hoang T, Chan AM (2007) Regulation of PTEN activity
by its carboxyl-terminal autoinhibitory domain. J Biol Chem 282: 23306–23315.
18. Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A (2004)
Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.
Science 303: 1179–1181.
19. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Garth P (2004) Thioredoxin-
1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity
and membrane binding: a mechanism for the functional loss of PTEN’s tumor
suppressor activity. Arch Biochem Biophys 429: 123–133.
20. Mehenni H, Lin-Marq N, Buchet-Poyau K, Reymond A, Collart MA, et al.
(2005) LKB1 interacts with and phosphorylates PTEN: a functional link between
two proteins involved in cancer predisposing syndromes. Hum Mol Genet 14:
2209–2219.
Expression and Cell Growth Inhibition by TPIP-C2
PLoS ONE | www.plosone.org 11 December 2011 | Volume 6 | Issue 12 | e2843321. Zhou M, Gu L, Findley HW, Jiang R, Woods WG (2003) PTEN reverses
MDM2-mediated chemotherapy resistance by interacting with p53 in acute
lymphoblastic leukemia cells. Cancer Res 63: 6357–6362.
22. Tang Y, Eng C (2006) PTEN autoregulates its expression by stabilization of p53
in a phosphatase-independent manner. Cancer Res 66: 736–742.
23. Chen H, Rossier C, Morris MA, Scott HS, Gos A, et al. (1999) A testis-specific
gene, TPTE, encodes a putative transmembrane tyrosine phosphatase and maps
to the pericentromeric region of human chromosomes 21 and 13, and to
chromosomes 15, 22, and Y. Hum Genet 105: 399–409.
24. Guipponi M, Yaspo ML, Riesselman L, Chen H, Sario ADe, et al. (2000)
Genomic structure of a copy of the human TPTE gene which encompasses
87 kb on the short arm of chromosome 21. Human Genet 107: 127–131.
25. Tapparel C, Reymond A, Girardet C, Guillou L, Lyle R, et al. (2003) The
TPTE gene family: cellular expression, subcellular localization and alternative
splicing. Gene 323: 189–199.
26. Walker SM, Downes CP, Leslie NR (2001) TPIP: a novel phosphoinositide 3-
phosphatase. Biochem J 360: 277–283.
27. Bajaj GD (2002) Molecular cloning and characterization of human cDNAs by a
simple repeat DNA probe: Identification of novel candidate genes. Ph.D. Thesis,
School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
28. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial
sequencing and analysis of the human genome. Nature 409: 860–921.
29. Agrawal S, Eng C (2006) Differential expression of novel naturally occurring
splice variants of PTEN and their functional consequences in Cowden syndrome
and sporadic breast cancer. Hum Mol Genet 15: 777–787.
30. Babich V, Aksenov N, Alexeenko V, Oei SL, Buchlow G, et al. (1999)
Association of some potential hormone response elements in human genes with
Alu family repeats. Gene 239: 341–349.
31. Yang Z, Boffelli D, Boonmark N, Schwartz K, Lawn R (1998) Apolipoprotein(a)
gene enhancer resides within a LINE element. J Biol Chem 273: 891–897.
32. Wu Y, Dowbenko D, Pisabarro M, Dillard-Telm L, Koeppen H, et al. (2001)
PTEN 2, a Golgi-associated testis-specific homologue of the PTEN tumor
suppressor lipid phosphatase. J Biol Chem 276: 21745–21753.
33. Rizo J, Su ¨dhof TC (1998) C2 domain, structure and function of a universal
Ca
2+-binding domain. J Biol Chem 273: 15879–15882.
34. Rahdar M, Inoue T, Meyer T, Zhang J, Vazquez F, et al. (2009) A
phosphorylation-dependent intramolecular interaction regulates the membrane
association and activity of the tumor suppressor PTEN. Proc Natl Acad Sci U S A
106: 480–485.
35. Lee JJ, Kim BC, Park MJ, Lee YS, Kim YN, et al. (2011) PTEN status switches
cell fate between premature senescence and apoptosis in glioma exposed to
ionizing radiation. Cell Death Differ 18: 666–677.
36. Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, et al. (2011)
Induction of apoptotic genes by a p73-PTEN complex in response to genotoxic
stress. J Biol Chem 286: 36631–36640.
37. Maier D, Jones G, Li X, Schonthal AH, Gratzl O, et al. (1999) The PTEN lipid
phosphatase domain is not required to inhibit invasion of glioma cells. Cancer
Res 59: 5479–5482.
38. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, et al. (2004)
PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human
bladder cancer cells even in the absence of its lipid phosphatase activity.
Oncogene 23: 6788–6797.
39. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, et al. (2006) Mechanistic insights
into maintenance of high p53 acetylation by PTEN. Mol Cell 23: 575–587.
40. Tian T, Nan KJ, Wang SH, Liang X, Lu CX, et al. (2010) PTEN regulates
angiogenesis and VEGF expression through phosphatase-dependent and -
independent mechanisms in HepG2 cells. Carcinogenesis 31: 1211–1219.
41. Cabarcas S, Watabe K, Schramm L (2010) Inhibition of U6 snRNA
transcription by PTEN. Online J Biol Sci 10: 114–125.
42. Law RH, Lukoyanova N, Voskoboinik I, Caradoc-Davies TT, Baran K, et al.
(2010) the structural basis for membrane binding and pore formation by
lymphocyte perforin. Nature 468: 447–451.
43. Dey I, Rath PC (2005) A novel rat genomic simple repeat DNA with RNA-
homology shows triplex (H-DNA)-like structure and tissue-specific RNA
expression. Biochem Biophys Res Commun 327: 276–286.
44. Sambrook J, Russell DW (2001) Molecular Cloning: A Laboratory Manual. 3rd
ed. Cold Spring Harbor Laboratory Press, New York.
Expression and Cell Growth Inhibition by TPIP-C2
PLoS ONE | www.plosone.org 12 December 2011 | Volume 6 | Issue 12 | e28433